☰

Marielle E. Yohe, Ph.D. - Publications

Affiliations: 
2007 Pharmacology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Medical Biophysics, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Rosenberg EM, Jian X, Soubias O, Yoon HY, Yadav MP, Hammoudeh S, Pallikkuth S, Akpan I, Chen PW, Maity TK, Jenkins LM, Yohe ME, Byrd RA, Randazzo PA. The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins. The Journal of Biological Chemistry. 102992. PMID 36758799 DOI: 10.1016/j.jbc.2023.102992  0.373
2020 Soubias O, Pant S, Heinrich F, Zhang Y, Roy NS, Li J, Jian X, Yohe ME, Randazzo PA, Lösche M, Tajkhorshid E, Byrd RA. Membrane surface recognition by the ASAP1 PH domain and consequences for interactions with the small GTPase Arf1. Science Advances. 6. PMID 32998886 DOI: 10.1126/sciadv.abd1882  0.328
2020 Liu Z, Zhang X, Lei H, Lam N, Carter S, Yockey O, Xu M, Mendoza A, Hernandez ER, Wei JS, Khan J, Yohe ME, Shern JF, Thiele CJ. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG. Nature Communications. 11: 911. PMID 32060262 DOI: 10.1038/S41467-020-14684-4  0.344
2020 Yohe ME, Gryder BE, Chou H, Song YK, Zhang X, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen J, Edmondson EJ, Difilippantionio S, Thomas CJ, Khan J. Abstract B17: MEK inhibition induces myogenic differentiation in RAS-driven rhabdomyosarcoma Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B17  0.368
2020 Yeung C, Gibson AE, Issaq SH, Oshima N, Yohe ME, Lei H, Rai G, Urban DJ, Johnson MS, Benevides GA, Squadrito GL, Eldridge S, Hamre J, Mendoza A, Shern JF, et al. Abstract PR08: Lactate dehydrogenase A is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Pr08  0.357
2020 Liu Z, Zhang X, Lei H, Lam N, Yockey O, Xu M, Mendoza A, Wei JS, Khan J, Yohe ME, Shern JF, Thiele CJ. Abstract B42: Mutant RAS represses CASZ1, a novel regulator of MYOD and MYOG, to inhibit embryonal rhabdomyosarcoma differentiation Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-B42  0.365
2020 Hebron KE, Feehan-Nelson O, Jian X, Girald SA, Randazzo PA, Yohe ME. Abstract B32: ASAP1 regulates differentiation in myoblasts and PAX-FOXO1 fusion-negative rhabdomyosarcoma Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-B32  0.389
2020 Cheuk A, Shivaprasad N, Schneider D, Yohe M, Tan M, Azorsa P, Sams R, Pomella S, Gryder B, Rota R, Stanton B, Wei J, Song Y, Wen X, Sindiri S, et al. Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A08  0.352
2019 Roy NS, Jian X, Soubias O, Zhai P, Hall JR, Dagher JN, Coussens NP, Jenkins LM, Luo R, Akpan IO, Hall MD, Byrd RA, Yohe ME, Randazzo PA. Interaction of the N terminus of ADP-ribosylation factor with the PH domain of the GTPase-activating protein ASAP1 requires phosphatidylinositol 4,5-bisphosphate. The Journal of Biological Chemistry. PMID 31591270 DOI: 10.1074/Jbc.Ra119.009269  0.505
2019 Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, Rai G, Urban DJ, Johnson MS, Benavides GA, Squadrito GL, Yohe ME, Lei H, Eldridge S, Hamre J, et al. Targeting glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing sarcoma. Cancer Research. PMID 31431459 DOI: 10.1158/0008-5472.Can-19-0217  0.331
2019 Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, Wiest O, Yohe ME, Shern JF, Qi J, Khan J. Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nature Communications. 10: 3004. PMID 31285436 DOI: 10.1038/S41467-019-11046-7  0.306
2019 Sztul E, Chen PW, Casanova JE, Cherfils J, Dacks JB, Lambright DG, Lee FS, Randazzo PA, Santy LC, Schürmann A, Wilhelmi I, Yohe ME, Kahn RA. ARF GTPases and their GEFs and GAPs: concepts and challenges. Molecular Biology of the Cell. 30: 1249-1271. PMID 31084567 DOI: 10.1091/Mbc.E18-12-0820  0.463
2018 Madigan JP, Hou F, Ye L, Hu J, Dong A, Tempel W, Yohe ME, Randazzo PA, Jenkins LMM, Gottesman MM, Tong Y. The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. The Journal of Biological Chemistry. PMID 30143532 DOI: 10.1074/Jbc.Ra118.003525  0.487
2018 Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Science Translational Medicine. 10. PMID 29973406 DOI: 10.1126/Scitranslmed.Aan4470  0.398
2018 McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer M, et al. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. Oncogene. PMID 29487419 DOI: 10.1038/S41388-017-0122-Y  0.371
2018 Yohe M, Lam N, Kowalczyk J, Thiele CJ. Abstract 3170: AKT/mTOR pharmacologic inhibition sensitizes RAS/MAPK-activated neuroblastoma cells to MEK1/2 inhibitors Cancer Research. 78: 3170-3170. DOI: 10.1158/1538-7445.Am2018-3170  0.344
2018 Roy NS, Zhai P, Jian X, Jenkins L, Luo R, Yohe ME, Randazzo PA. Interaction of the ASAP1 PH Domain with the N Terminus of ARF1 is Controlled by Conformational Switching Biophysical Journal. 114: 405a. DOI: 10.1016/J.Bpj.2017.11.2245  0.365
2017 Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song YK, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discovery. PMID 28446439 DOI: 10.1158/2159-8290.Cd-16-1297  0.398
2017 Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri S, Gryder B, Oliveira ML, Ramakrishnan A, Tang Q, Chen EY, Petur Nielsen G, Khan J, Langenau DM. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife. 6. PMID 28080960 DOI: 10.7554/Elife.19214  0.375
2017 Liu Z, Lam N, Mendoza A, Wei JS, Shern JF, Yohe M, Khan J, Thiele CJ. Abstract 5522: Novel myogenic differentiation transcription factor CASZ1 suppresses rhabdomyosarcoma tumor growth Cancer Research. 77: 5522-5522. DOI: 10.1158/1538-7445.Am2017-5522  0.345
2016 Roy NS, Yohe ME, Randazzo PA, Gruschus JM. Allosteric properties of PH domains in Arf regulatory proteins. Cellular Logistics. 6: e1181700. PMID 27294009 DOI: 10.1080/21592799.2016.1181700  0.48
2016 Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri S, Gryder B, Oliveira ML, Ramakrishnan A, Tang Q, Chen EY, Nielsen GP, Khan J, Langenau DM. Author response: Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma Elife. DOI: 10.7554/Elife.19214.026  0.32
2016 Gryder BE, Yohe ME, Shern J, Chou H, Song Y, Patidar R, Li S, Sindiri S, Cleveland A, Liao H, Wen X, Zhang X, Mathews-Griner L, Guha R, Shinn P, et al. Abstract PR16: Targeting the chromatin architecture established by PAX3-FOXO1 in rhabdomyosarcoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr16  0.419
2016 Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Griner LAM, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, ... ... Yohe ME, et al. Abstract B31: Combined siRNA and small molecule screening identifies Aurora B kinase as an effective target in MYCN-driven neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B31  0.324
2016 Yohe ME, Gryder BE, Shern JF, Song YK, Liao H, Chou H, Sindiri S, Mendoza A, Zhang X, Guha R, Haines DC, Madigan JP, Wei JS, Ferrer M, Thomas CJ, et al. Abstract A25: Reprogramming RAS-driven rhabdomyosarcoma via MEK inhibition Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-A25  0.358
2016 Shivaprasad N, Xiong Y, Yohe M, Schneider D, Shern J, Baskar S, Dimitrov D, Sorenson P, Orentas R, Khan J. 649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma Molecular Therapy. 24: S257-S258. DOI: 10.1016/S1525-0016(16)33457-8  0.347
2015 Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, ... ... Yohe ME, et al. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget. PMID 26497213 DOI: 10.18632/Oncotarget.6208  0.324
2015 Jian X, Tang WK, Zhai P, Roy NS, Luo R, Gruschus JM, Yohe ME, Chen PW, Li Y, Byrd RA, Xia D, Randazzo PA. Molecular Basis for Cooperative Binding of Anionic Phospholipids to the PH Domain of the Arf GAP ASAP1. Structure (London, England : 1993). PMID 26365802 DOI: 10.1016/J.Str.2015.08.008  0.377
2015 McKinnon T, Venier R, Dickson BC, Kabaroff L, Alkema M, Chen L, Shern JF, Yohe ME, Khan J, Gladdy RA. Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation. Oncotarget. 6: 14220-32. PMID 25992772 DOI: 10.18632/Oncotarget.3856  0.321
2015 Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J. Clonality and evolutionary history of rhabdomyosarcoma. Plos Genetics. 11: e1005075. PMID 25768946 DOI: 10.1371/Journal.Pgen.1005075  0.303
2015 Baskar S, Shivaprasad N, Zhu Z, Dimitrov D, Sigrist M, Sorensen P, Yohe M, Shern J, Maris J, Mackall C, Khan J. Abstract 2488: FGFR4 as a potential therapeutic target for monoclonal antibody based intervention in rhabdomyosarcoma Cancer Research. 75: 2488-2488. DOI: 10.1158/1538-7445.Am2015-2488  0.31
2008 Yohe ME, Rossman K, Sondek J. Role of the C-terminal SH3 domain and N-terminal tyrosine phosphorylation in regulation of Tim and related Dbl-family proteins. Biochemistry. 47: 6827-39. PMID 18537266 DOI: 10.1021/Bi702543P  0.749
2007 Mitin N, Betts L, Yohe ME, Der CJ, Sondek J, Rossman KL. Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nature Structural & Molecular Biology. 14: 814-23. PMID 17704816 DOI: 10.1038/Nsmb1290  0.741
2007 Rojas RJ, Yohe ME, Gershburg S, Kawano T, Kozasa T, Sondek J. Galphaq directly activates p63RhoGEF and Trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain. The Journal of Biological Chemistry. 282: 29201-10. PMID 17606614 DOI: 10.1074/Jbc.M703458200  0.728
2007 Yohe ME, Rossman KL, Gardner OS, Karnoub AE, Snyder JT, Gershburg S, Graves LM, Der CJ, Sondek J. Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif. The Journal of Biological Chemistry. 282: 13813-23. PMID 17337446 DOI: 10.1074/Jbc.M700185200  0.752
2005 Smith WJ, Hamel B, Yohe ME, Sondek J, Cerione RA, Snyder JT. A Cdc42 mutant specifically activated by intersectin. Biochemistry. 44: 13282-90. PMID 16201754 DOI: 10.1021/Bi050591B  0.624
2004 Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S. Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. Journal of Virology. 78: 4197-206. PMID 15047835 DOI: 10.1128/Jvi.78.8.4197-4206.2004  0.348
Show low-probability matches.